Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
18 déc. 2023 07h00 HE
|
Invivyd
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
09 nov. 2023 16h01 HE
|
Invivyd
Enrollment completed in CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the prevention of symptomatic COVID-19Company expects to have initial CANOPY primary endpoint data by late 2023...
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights
02 nov. 2023 16h01 HE
|
Invivyd
WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd to Participate in Upcoming Investor Conferences
31 oct. 2023 16h01 HE
|
Invivyd
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19
11 sept. 2023 07h00 HE
|
Invivyd
WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd to Participate in Upcoming Investor Conferences
06 sept. 2023 07h00 HE
|
Invivyd
WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Appoints William Duke as Chief Financial Officer
05 sept. 2023 07h00 HE
|
Invivyd
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights
10 août 2023 16h01 HE
|
Invivyd
Reported positive initial Phase 1 VYD222 clinical trial data, including favorable safety data and robust serum neutralizing titers from all three dose levels testedPlans to pursue rapid initiation of...
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights
03 août 2023 16h01 HE
|
Invivyd
WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Announces Appointment of Sara Cotter to Board Of Directors
27 juil. 2023 16h01 HE
|
Invivyd
WALTHAM, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...